BMO Capital analyst Jim Birchenough views disappointing data from Galectin Therapeutics (NASDAQ: GALT) as a positive for Intercept Pharmaceuticals' (NASDAQ ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE